CLPTM1L
Lipid scramblase CLPTM1L
Also known as: CLP1L_HUMAN, CRR9, FLJ14400
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96KA5
- Gene
- CLPTM1L
- Ensembl
- ENSG00000049656
- Chromosome
- 5
- Canonical length
- 538 aa
- Protein class
- Predicted membrane proteins, Transporters
- Subcellular location
- Endoplasmic reticulum
OverviewNCBI Gene
The protein encoded by this gene is a membrane protein whose overexpression in cisplatin-sensitive cells causes apoptosis. Polymorphisms in this gene have been reported to increase susceptibility to several cancers, including lung, pancreatic, and breast cancers. [provided by RefSeq, Nov 2015]
Canonical amino-acid sequenceUniProt
538 residues, UniProt reviewed canonical sequence.
>Q96KA5|CLPTM1L
1 MWSGRSSFTS LVVGVFVVYV VHTCWVMYGI VYTRPCSGDA NCIQPYLARR PKLQLSVYTT
61 TRSHLGAENN IDLVLNVEDF DVESKFERTV NVSVPKKTRN NGTLYAYIFL HHAGVLPWHD
121 GKQVHLVSPL TTYMVPKPEE INLLTGESDT QQIEAEKKPT SALDEPVSHW RPRLALNVMA
181 DNFVFDGSSL PADVHRYMKM IQLGKTVHYL PILFIDQLSN RVKDLMVINR STTELPLTVS
241 YDKVSLGRLR FWIHMQDAVY SLQQFGFSEK DADEVKGIFV DTNLYFLALT FFVAAFHLLF
301 DFLAFKNDIS FWKKKKSMIG MSTKAVLWRC FSTVVIFLFL LDEQTSLLVL VPAGVGAAIE
361 LWKVKKALKM TIFWRGLMPE FQFGTYSESE RKTEEYDTQA MKYLSYLLYP LCVGGAVYSL
421 LNIKYKSWYS WLINSFVNGV YAFGFLFMLP QLFVNYKLKS VAHLPWKAFT YKAFNTFIDD
481 VFAFIITMPT SHRLACFRDD VVFLVYLYQR WLYPVDKRRV NEFGESYEEK ATRAPHTDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CLPTM1L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 6
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 128 nTPM
Expression across tissuesHPA
Tissue
- liver: 128 nTPM
- pancreas: 72 nTPM
- stomach: 66 nTPM
- salivary gland: 61 nTPM
- spleen: 57 nTPM
- kidney: 57 nTPM
Single-cell type
- plasma cells: 267 nCPM
- alveolar cells type 1: 222 nCPM
- gastric chief cells: 116 nCPM
- alveolar cells type 2: 111 nCPM
- hepatocytes: 109 nCPM
- parietal cells: 101 nCPM
Immune cell
- naive B-cell: 10 nTPM
- eosinophil: 10 nTPM
- NK-cell: 10 nTPM
- plasmacytoid DC: 9.3 nTPM
- non-classical monocyte: 8.1 nTPM
- T-reg: 7.8 nTPM
Brain region
- choroid plexus: 42 nTPM
- midbrain: 37 nTPM
- hypothalamus: 26 nTPM
- spinal cord: 23 nTPM
- thalamus: 23 nTPM
- medulla oblongata: 23 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.65
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.57
- DepMap mean gene effect
- 0.19
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 16% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CLPTM1L as an antibody target. Whether an autoantibody or antibody against CLPTM1L could matter depends on whether native CLPTM1L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CLPTM1L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CLPTM1L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...